Esomeprazole News and Research

RSS
Esomeprazole is a drug that blocks acid from being made in the stomach. It is used to treat acid reflux disease and to prevent certain types of gastrointestinal ulcers. Esomeprazole magnesium is being studied in the prevention of esophageal cancer and in the treatment of other conditions, including side effects of chemotherapy. It is a type of anti-ulcer agent. Also called esomeprazole and Nexium.
Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

POZEN receives milestone payment from AstraZeneca for FDA approval of VIMOVO

POZEN receives milestone payment from AstraZeneca for FDA approval of VIMOVO

FDA warns on possible fracture risk with proton pump inhibitors use

FDA warns on possible fracture risk with proton pump inhibitors use

VIMOVO delayed-release tablets receive FDA approval

VIMOVO delayed-release tablets receive FDA approval

DIS serves as marker for new methods to diagnose NERD

DIS serves as marker for new methods to diagnose NERD

Concurrent use of proton-pump inhibitor and clopidogrel does not elevate cardiovascular risk

Concurrent use of proton-pump inhibitor and clopidogrel does not elevate cardiovascular risk

POZEN reports net loss of $6.9M for year ended December 31, 2009

POZEN reports net loss of $6.9M for year ended December 31, 2009

Concomitant use of dexlansoprazole and other PPIs with Plavix: TGRD U.S. initiates trial

Concomitant use of dexlansoprazole and other PPIs with Plavix: TGRD U.S. initiates trial

Teva Pharmaceutical Industries enters into two definitive agreements with AstraZeneca

Teva Pharmaceutical Industries enters into two definitive agreements with AstraZeneca

FDA: Plavix-Prilosec combination may reduce anti-clotting effect

FDA: Plavix-Prilosec combination may reduce anti-clotting effect

Third-quarter fiscal 2009 results announced by POZEN

Third-quarter fiscal 2009 results announced by POZEN

POZEN announces Phase I study results of PA65020

POZEN announces Phase I study results of PA65020

AstraZeneca and POZEN announce the pivotal data from two POZEN clinical trials

AstraZeneca and POZEN announce the pivotal data from two POZEN clinical trials

New Drug Application for VIMOVO accepted by U.S. Food and Drug Administration

New Drug Application for VIMOVO accepted by U.S. Food and Drug Administration

Radiofrequency ablation eradicates problems in most patients with Barrett's esophagus

Radiofrequency ablation eradicates problems in most patients with Barrett's esophagus

Anti-clotting action of clopidogrel (Plavix) reduced by common heartburn drugs

Anti-clotting action of clopidogrel (Plavix) reduced by common heartburn drugs

PPI prescribed for asthma ineffective and too expensive

PPI prescribed for asthma ineffective and too expensive

Treatment for acid reflux does not improve asthma symptoms

Treatment for acid reflux does not improve asthma symptoms

Prescription heartburn medications do not ease asthma symptoms

Prescription heartburn medications do not ease asthma symptoms

National study results change common method of treating asthma

National study results change common method of treating asthma